GLA antibody - 100 µg
Host : Mouse
Clonality: Monoclonal
Clone: 7F1
Isotype: IgG2a
Immunogen: galactosidase, alpha
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 49 kDa
Uniprot: P06280
Gene id: 2717
Background: GLA, also named as Melibiase, Agalsidase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
Field of research: Cardiovascular, Metabolism, Signal Transduction
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC, IF
Dilution: WB: 1:500-1:2000; IHC: 1:20-1:200; IF: 1:20-1:200
Target: GLA
Purification: Protein A+G purification
Reactivity: Human
![]()
Clonality: Monoclonal
Clone: 7F1
Isotype: IgG2a
Immunogen: galactosidase, alpha
Purity: ≥95% as determined by SDS-PAGE
Form: Liquid
Molecular weight: 49 kDa
Uniprot: P06280
Gene id: 2717
Background: GLA, also named as Melibiase, Agalsidase and Alpha-galactosidase A, belongs to the glycosyl hydrolase 27 family. It hydrolyzes terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
Field of research: Cardiovascular, Metabolism, Signal Transduction
Storage conditions: PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months(Avoid repeated freeze
thaw cycles.)
Applications: ELISA, WB, IHC, IF
Dilution: WB: 1:500-1:2000; IHC: 1:20-1:200; IF: 1:20-1:200
Target: GLA
Purification: Protein A+G purification
Reactivity: Human